Molecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, University of Sydney, Sydney, New South Wales 2006, Australia.
Molecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, University of Sydney, Sydney, New South Wales 2006, Australia; Melbourne Dementia Research Centre, The Florey Institute of Neuroscience & Mental Health, The University of Melbourne, Parkville, VIC, Australia.
Biochim Biophys Acta Mol Basis Dis. 2020 Oct 1;1866(10):165844. doi: 10.1016/j.bbadis.2020.165844. Epub 2020 May 29.
The iron-containing protein, acireductone dioxygenase 1 (ADI1), is a dioxygenase important for polyamine synthesis and proliferation. Using differential proteomics, the studies herein demonstrated that ADI1 was significantly down-regulated by cellular iron depletion. This is important, since ADI1 contains a non-heme, iron-binding site critical for its activity. Examination of multiple human cell-types demonstrated a significant decrease in ADI1 mRNA and protein after incubation with iron chelators. The decrease in ADI1 after iron depletion was reversible upon incubation of cells with the iron salt, ferric ammonium citrate (FAC). A significant decrease in ADI1 mRNA levels was observed after 14 h of iron depletion. In contrast, the chelator-mediated reduction in ADI1 protein occurred earlier after 10 h of iron depletion, suggesting additional post-transcriptional regulation. The proteasome inhibitor, MG-132, prevented the iron chelator-mediated decrease in ADI1 expression, while the lysosomotropic agent, chloroquine, had no effect. These results suggest an iron-dependent, proteasome-mediated, degradation mechanism. Poly r(C)-binding protein (PCBPs) 1 and 2 act as iron delivery chaperones to other iron-containing dioxygenases and were shown herein for the first time to be regulated by iron levels. Silencing of PCBP1, but not PCBP2, led to loss of ADI1 expression. Confocal microscopy co-localization studies and proximity ligation assays both demonstrated decreased interaction of ADI1 with PCBP1 and PCBP2 under conditions of iron depletion using DFO. These data indicate PCBP1 and PCBP2 interact with ADI1, but only PCBP1 plays a role in ADI1 expression. In fact, PCBP2 appeared to play an accessory role, being involved as a potential co-chaperone.
含铁蛋白,还原酮双加氧酶 1(ADI1),是一种对多胺合成和增殖很重要的双加氧酶。通过差异蛋白质组学研究,本文证明 ADI1 会被细胞铁耗竭显著下调。这很重要,因为 ADI1 含有一个非血红素铁结合位点,对其活性至关重要。对多种人类细胞类型的研究表明,在用铁螯合剂孵育后,ADI1 的 mRNA 和蛋白显著减少。在用铁盐柠檬酸铁铵(FAC)孵育细胞后,铁耗竭后 ADI1 的减少是可逆的。在铁耗竭 14 小时后,观察到 ADI1 mRNA 水平显著降低。相比之下,在用铁螯合剂处理 10 小时后,ADI1 蛋白的减少更早出现,表明存在额外的转录后调控。蛋白酶体抑制剂 MG-132 可阻止铁螯合剂介导的 ADI1 表达减少,而溶酶体趋化剂氯喹则没有影响。这些结果表明存在一种铁依赖性、蛋白酶体介导的降解机制。多聚 r(C)结合蛋白(PCBPs)1 和 2 作为铁传递伴侣作用于其他含铁双加氧酶,本文首次证明其受铁水平调节。沉默 PCBP1,但不是 PCBP2,导致 ADI1 表达丧失。共聚焦显微镜共定位研究和邻近连接测定均表明,在使用 DFO 的铁耗竭条件下,ADI1 与 PCBP1 和 PCBP2 的相互作用减少。这些数据表明 PCBP1 和 PCBP2 与 ADI1 相互作用,但只有 PCBP1 在 ADI1 表达中起作用。事实上,PCBP2 似乎发挥了辅助作用,作为潜在的共伴侣参与其中。